Amitriptyline hydrochloride is under clinical development by AlgoTherapeutix and currently in Phase I for Diabetic Peripheral Neuropathy. According to GlobalData, Phase I drugs for Diabetic Peripheral Neuropathy have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amitriptyline hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amitriptyline hydrochloride overview
AlgoTherapeutix overview
AlgoTherapeutix is a biotechnology company that is engaged in developing and commercializing innovative medicines for complex pain, focusing on chemotherapy-induced neuropathic pain and erythromelalgia. The company is headquartered in Paris, Ile-de-France, France.
For a complete picture of Amitriptyline hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
